Holen Sie sich die Stockscreener-App
99.74
0.02%
0.02
Handel nachbörslich:
99.74
Schlusskurs vom Vortag:
$99.72
Offen:
$99.92
24-Stunden-Volumen:
846.97K
Relative Volume:
0.65
Marktkapitalisierung:
$6.51B
Einnahmen:
$1.54B
Nettoeinkommen (Verlust:
$233.56M
KGV:
29.62
EPS:
3.3669
Netto-Cashflow:
$348.64M
1W Leistung:
-0.81%
1M Leistung:
-1.12%
6M Leistung:
+31.88%
1J Leistung:
+93.78%
1-Tages-Spanne:
$99.72
$99.99
1-Wochen-Bereich:
$99.69
$100.96
52-Wochen-Spanne:
$49.67
$111.86
Lantheus Holdings Inc Stock (LNTH) Company Profile
Firmenname
Lantheus Holdings Inc
Sektor
Telefon
978 671-8001
Adresse
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, TEVA, HLN, ZTS, VTRS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
99.74 | 6.51B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
18.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.26 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
71.05 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
VTRS
Viatris Inc
|
17.83 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-12 | Hochstufung | Truist | Hold → Buy |
| 2025-10-08 | Herabstufung | Goldman | Buy → Neutral |
| 2025-08-12 | Herabstufung | Truist | Buy → Hold |
| 2024-12-18 | Eingeleitet | Goldman | Buy |
| 2024-09-03 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-07-10 | Bestätigt | JMP Securities | Mkt Outperform |
| 2023-12-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-12-04 | Eingeleitet | TD Cowen | Outperform |
| 2023-09-29 | Eingeleitet | William Blair | Outperform |
| 2023-03-08 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-11-30 | Eingeleitet | SVB Leerink | Outperform |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-05-09 | Eingeleitet | B. Riley Securities | Buy |
| 2022-04-13 | Eingeleitet | Truist | Buy |
| 2021-02-01 | Eingeleitet | SVB Leerink | Outperform |
| 2020-06-29 | Fortgesetzt | Jefferies | Buy |
| 2019-08-16 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2017-11-02 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-11-08 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-09-23 | Fortgesetzt | Credit Suisse | Neutral |
| 2016-02-24 | Bestätigt | RBC Capital Mkts | Outperform |
| 2015-12-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2015-09-30 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2015-07-20 | Eingeleitet | Credit Suisse | Outperform |
| 2015-07-20 | Eingeleitet | Jefferies | Buy |
| 2015-07-20 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2015-07-20 | Eingeleitet | Robert W. Baird | Outperform |
| 2015-07-20 | Eingeleitet | Wells Fargo | Outperform |
Alle ansehen
Lantheus Holdings Inc Aktie (LNTH) Neueste Nachrichten
Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval - finance.yahoo.com
Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval - finance.yahoo.com
Lantheus stock trades at USD 99.72 after FDA approval - AD HOC NEWS
FDA approves Lantheus’ Bravnetsa for GEP-NETs - DOTmed
FDA approval for Lantheus’ Bravnetsa - The Pharma Letter
Lantheus Holdings, Inc. (LNTH) Stock Forecasts - Yahoo! Finance Canada
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. ( - The Daily Tribune News
Curium Resets FTC Clock On $8B Lantheus Take-Private Deal - Law360
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
LNTH Stock Drops After-Hours As Curium's $7B Offer Comes In Below Market Value - Stocktwits
Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally - finance.yahoo.com
3 Reasons LNTH is Risky and 1 Stock to Buy Instead - finance.yahoo.com
Lantheus Holdings wins FDA approval for Bravnetsa before Curium vote - Mugglehead Investment Magazine
Lantheus wins final FDA approval for BRAVNETSA (lutetium Lu 177 dotatate( for GEP-NETs - app.dealroom.co
LNTH Looks 11.3% Overvalued on GF Value™ After FDA Approval - GuruFocus
Lantheus Holdings, Inc. Receives Final FDA Approval for BRAVNETSA for Treatment of GEP-NETs - marketscreener.com
Lantheus Says Curium Resubmits Antitrust Filing for Merger - Moomoo
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors By Investing.com - Investing.com Australia
FDA approves Lantheus’ BRAVNETSA for neuroendocrine tumors - Investing.com India
Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs - marketscreener.com
A radioactive cancer treatment becomes the first approved through the FDA’s abbreviated drug pathway - Stock Titan
The Technical Signals Behind (LNTH) That Institutions Follow - Stock Traders Daily
Lantheus Holdings stock faces a new Curium review window - AD HOC NEWS
LNTH Looks 11.3% Overvalued on GF Value™ - GuruFocus
Lantheus Holdings, Inc. (LNTH) Stock Analysis: A Healthcare Powerhouse with a 7.15% Potential Upside - DirectorsTalk Interviews
Lantheus Holdings, Inc. (LNTH): Investor Outlook On A Potential 7.47% Upside - DirectorsTalk Interviews
(LNTH) Risk Channels and Responsive Allocation - Stock Traders Daily
LNTH, ITGR and CZR Deals Face Investor Scrutiny - stl.news
Lantheus Holdings Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lantheus Holdings, Inc.LNTH - Business Wire
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Entities Hold 20.9% Stake in Radiopharm Theranostics (NASDAQ: RADX) Including Significant Options - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout - Stock Titan
Radioligand Therapy Market to Grow from USD 2.98 Billion in 2025 to USD 15.85 Billion by 2035, at a CAGR of 18.2% - GlobeNewswire Inc.
Lantheus Holdings, Inc. (LNTH) Stock Analysis: Exploring Growth Potential in the Healthcare Sector - DirectorsTalk Interviews
Lantheus alpha therapy, CATX director, sells $131k in stock By Investing.com - Investing.com Australia
Lantheus alpha therapy, CATX director, sells $131k in stock - Investing.com
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - kalkinemedia.com
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com India
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
Technical Reactions to LNTH Trends in Macro Strategies - Stock Traders Daily
Finanzdaten der Lantheus Holdings Inc-Aktie (LNTH)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):